Raymond James Financial
ATNM icon

Raymond James Financial’s Actinium Pharmaceuticals ATNM Stock Holding History

Raymond James Financial’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,165
Closed -$1.63K – 5088
2025
Q2 		$1.63K Buy
+1,165
New +$1.74K ﹤0.01% 6457

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's ATNM Position: Q3 2025 in Review

Raymond James Financial sold out of Actinium Pharmaceuticals (ATNM) in Q3 2025, closing a stake of 1,165 shares — an estimated $1.63K sold.

Raymond James Financial first reported a position in ATNM in Q2 2025 and held it in 1 quarter. The position peaked at $1.63K in Q2 2025. 61 funds tracked by Wall St. Rank hold ATNM as of Q3 2025.

  • Raymond James Financial reported no remaining Actinium Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,165 Actinium Pharmaceuticals shares in Q3 2025, an estimated $1.63K.
  • Raymond James Financial first reported a position in Actinium Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Actinium Pharmaceuticals position peaked at $1.63K in Q2 2025.
  • 61 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.